XML 22 R11.htm IDEA: XBRL DOCUMENT v3.7.0.1
Related Parties Balances and Transactions
9 Months Ended
Jun. 30, 2017
Related Parties Balances and Transactions [Abstract]  
RELATED PARTIES BALANCES AND TRANSACTIONS

6. RELATED PARTIES BALANCES AND TRANSACTIONS

 

The following is a list of related parties to which the Company has transactions with:

 

Eugene Jiang is the Chief Executive Officer of the Company, the owner of BioLite, Inc and one of the directors and common stock shareholders of BioFirst Corporation.

 

Amount due to related party

 

Amount due to related party consisted of the following as of the periods indicated:

 

  June 30,
2017
  September 30,
2016
 
       
BioLite, Inc $-  $6,500,000 
BioFirst Corporation  950,000   - 
YuanGene Corporation  3,000   - 
Balance as at the ended of the period / year $953,000  $6,500,000 

 

Related party transactions

 

Unsecured borrowings from related parties consisted of the following for the periods indicated:

 

  June 30,
2017
  September 30,
2016
 
       
BioFirst Corporation $950,000  $        - 
YuanGene Corporation  3,000   - 
Total $953,000  $- 

 

On January 26, 2017, the Company entered into a loan agreement with the lender party thereto, BioFirst Corporation, a company incorporated in Taiwan, Republic of China, for a total commitment (non-secured indebtedness) of $950,000 to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to remit the interest payment monthly to the lender. The loan will be matured on February 1, 2018.

 

During the quarter ended December 31, 2016, the Company provided a one-time consulting service to LionGene Corporation, a shareholder of the Company for $70,000.

 

On May 26, 2017, the Company entered into a co-development agreement (the “Co-Dev Agreement”) with Rgene Corporation, a shareholder of the Company, to co-develop and commercialize certain products that are included in the Sixth Product as defined in the Addendum with Biolite. Per the payment term, $90,000 which is 3% of the total agreement of $3,000,000 to be paid by Rgene, was received upon signing of the agreement by both parties.

 

Interest expense related to this indebtedness is $28,500 and $0 for the three months ended June 30, 2017 and 2016, respectively and $47,500 and $0 for the nine months ended June 30, 2017 and 2016, respectively. Accrued interest related to this borrowing is $9,500 and $0 as of June 30, 2017 and September 30, 2016, respectively.